New drug siplizumab tested in ALS patients – early trial begins
NCT ID NCT06453668
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of siplizumab, a drug that may calm the immune system, in 48 adults newly diagnosed with ALS. Researchers will monitor side effects and how the drug moves through the body. The goal is to see if it is safe enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
siplizumab (TCD601)
What this could lead to
If safe and effective, siplizumab could slow ALS progression by targeting the immune system, offering a new treatment option.
What could go wrong
This is an early Phase 1 trial with only 48 people, focused on safety. It may not show benefit, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne University Hospital Malmö
RECRUITINGMalmö, 205 02, Sweden
Contact
-
Studieenheten Akademiskt Specialistcentrum
RECRUITINGStockholm, 171 77, Sweden
Contact
-
Umeå University Hospital
RECRUITINGUmeå, 901 85, Sweden
Contact